Legend Biotech Corp
LEGNHealthcare|Biotechnology|USA
$27.08
-0.32 (-1.17%)
Tangible Book
$5.02
About
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Stock Price
-31.8%(1Y)
Pipeline Summary
45 total trials30
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Active: 2Terminated: 18Unknown: 8Recruiting: 9NOT_YET_RECRUITING: 4Withdrawn: 3Completed: 1
Active Trials (11)
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
NCT05539430Gastric Cancer
Phase 1Active
Enrollment: 56 participants
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
NCT05680922Small Cell Lung Cancer Extensive Stage
Phase 1Active
Enrollment: 41 participants
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06313957Relapsed B-cell Non-Hodgkin Lymphoma
Phase 1Recruiting
Enrollment: 42 participants
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
NCT07331272Systemic Lupus Erythematosus (SLE)
Phase 1Recruiting
Enrollment: 38 participants
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07294625Multiple Myeloma
Early P1Recruiting
Enrollment: 36 participants
BioScore
5.7/10
Watchlist
Ownership
Recent Insider Trades
Casey Patrick JohnSELL
2026-06-306,000 shares @ $14.8
Huang YingSELL
2026-06-255,566 shares @ $14.78
Huang YingSELL
2026-03-259,936 shares @ $8.77
Recent News
2026-07-07 16:39:05
2026-07-02 22:08:28
2026-06-18 16:28:41
2026-06-18 14:30:06
2026-06-18 06:56:15
Data last updated: Jul 12, 2026, 07:28 PM